Evidence map›Paper›PMID 27750111›Full record

ArticleVirology2016

A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection.

Wanbo Tai, Guangyu Zhao, Shihun Sun, Yan Guo, Yufei Wang, Xinrong Tao, Chien-Te K Tseng, Fang Li, Shibo Jiang, Lanying Du and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
82citing papers in PubMed, 1 pooled it
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

82 citing papers in PubMed, 1 synthesis or guideline pooled it, 111 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Advances in mRNA and other vaccines against MERS-CoV.Translational research : the journal of laboratory and clinical medicine · 2022
    Review

22 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 3 countries.

Wanbo TaiState Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China; Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA.
Guangyu ZhaoState Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China.
Shihun SunState Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China.
Yan GuoState Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China.
Yufei WangState Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China; Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA.
Xinrong TaoDepartment of Microbiology and Immunology and Center for Biodefense and Emerging Disease, University of Texas Medical Branch, Galveston, TX, USA.
Chien-Te K TsengDepartment of Microbiology and Immunology and Center for Biodefense and Emerging Disease, University of Texas Medical Branch, Galveston, TX, USA.
Fang LiDepartment of Pharmacology, University of Minnesota Medical School, Minneapolis, MN, USA.
Shibo JiangLindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA; Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Basic Medical College and Institute of Medical Microbiology, Fudan University, Shanghai, China. Electronic address: sjiang@nybc.org.
Lanying DuLindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA. Electronic address: ldu@nybc.org.
Yusen ZhouState Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China. Electronic address: yszhou@bmi.ac.cn.
Institute of Microbiology · CNNew York Blood Center · USThe University of Texas Medical Branch at Galveston · USInstitute of Microbiology · BYShanghai Medical College of Fudan University · CNUniversity of Minnesota Medical Center · US

Funding

RBD recombinant protein-based SARS vaccine for biodefenseR01AI098775 · NIAID · BAYLOR COLLEGE OF MEDICINE · PI BOTTAZZI, MARIA ELENA, HOTEZ, PETER J · 2012 to 2016
$6.1M
Receptor recognition mechanisms of coronavirusesR01AI089728 · NIAID · UNIVERSITY OF MINNESOTA · PI Fang Li, Timothy Patrick Sheahan · 2010 to 2026
$4.7M
Enhancing potency of the MERS vaccine by a novel ASP-1+alum adjuvant combinationU01AI124260 · NIAID · NEW YORK BLOOD CENTER · PI DU, LANYING, LUSTIGMAN, SARA · 2016 to 2020
$3.0M
Critical neutralizing domain-based vaccines against new SARS-like virus hCoV-EMCR21AI109094 · NIAID · NEW YORK BLOOD CENTER · PI DU, LANYING · 2014 to 2015
$466k
NIAID NIH HHS R01 AI089728NIAID NIH HHS R01 AI098775NIAID NIH HHS R21 AI109094NIAID NIH HHS U01 AI124260
6 · The paper itself

Abstract

Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV) was first identified in 2012, and it continues to threaten human health worldwide. No MERS vaccines are licensed for human use, reinforcing the urgency to develop safe and efficacious vaccines to prevent MERS. MERS-CoV spike protein forms a trimer, and its receptor-binding domain (RBD) serves as a vaccine target. Nevertheless, the protective efficacy of RBD in its native trimeric form has never been evaluated. In this study, a trimeric protein, RBD-Fd, was generated by fusing RBD with foldon trimerization motif. It bound strongly to the receptor of MERS-CoV, dipeptidyl peptidase 4 (DPP4), and elicited robust RBD-specific neutralizing antibodies in mice, maintaining long-term neutralizing activity against MERS-CoV infection. RBD-Fd potently protected hDPP4 transgenic mice from lethal MERS-CoV challenge. These results suggest that MERS-CoV RBD in its trimeric form maintains native conformation and induces protective neutralizing antibodies, making it a candidate for further therapeutic development.

Indexed as

AnimalsAntibodies, NeutralizingAntibodies, ViralCoronavirus InfectionsDipeptidyl Peptidase 4FemaleHumansMiceMice, Inbred BALB CMice, TransgenicMiddle East Respiratory Syndrome CoronavirusProtein BindingProtein DomainsReceptors, VirusSpike Glycoprotein, CoronavirusAntibodies, NeutralizingAntibodies, ViralDipeptidyl Peptidase 4DPP4 protein, humanDpp4 protein, mouseReceptors, VirusSpike Glycoprotein, CoronavirusFoldon trimerization motifhDPP4-transgenic miceMERSMERS-CoVNeutralizationProtectionReceptor-binding domainSpike protein

Identifiers

PMID27750111
PMCPMC5167628
OpenAlexW2531641604

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.